UBS Group
IBER.WS

UBS Group’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History

UBS Group’s Portfolio IBER.WS Stock Details IBER.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-102
Closed – – 11541
2022
Q3 		$0 Sell
102
-498
-83% -$53 ﹤0.01% 11466
2022
Q2 		$0 Sell
600
-1,100
-65% -$190 ﹤0.01% 11449
2022
Q1 		$0 Buy
+1,700
New +$511 ﹤0.01% 11325

Other funds holding IBER.WS

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group's IBER.WS Position: Q4 2022 in Review

UBS Group sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q4 2022, closing a stake of 102 shares.

UBS Group first reported a position in IBER.WS in Q1 2022 and held it in 3 quarters. The position peaked at $0 in Q3 2022. 33 funds tracked by Wall St. Rank hold IBER.WS as of Q4 2022.

  • UBS Group reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q4 2022 after selling out during the quarter.
  • UBS Group sold 102 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q4 2022.
  • UBS Group first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q1 2022 and held it in 3 quarters.
  • UBS Group's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $0 in Q3 2022.
  • 33 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.